VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC

Purpose: We aim to characterize VTX-2337, a novel Toll-like receptor (TLR) 8 agonist in clinical development, and investigate its potential to improve monoclonal antibody–based immunotherapy that includes the activation of natural killer (NK) cells. Experimental Design: HEK-TLR transfectants were used to compare the selectivity and potency of VTX-2337, imiquimod, CpG ODN2006, and CL075. The ability of VTX-2337 to induce cytokine and chemokine production from human peripheral blood mononuclear cells (PBMC) and activation of specific immune cell subsets was examined. The potential for VTX-2337 to activate NK cell activity through direct and indirect mechanisms was also investigated. Finally, we tested the potential for VTX-2337 to augment antibody-dependent cell-mediated cytotoxicity (ADCC), especially in individuals with low-affinity FcγR3A single-nucleotide polymorphism (SNP). Results: VTX-2337 selectively activates TLR8 with an EC50 of about 100 nmol/L and stimulates production of TNFα and interleukin (IL)-12 from monocytes and myeloid dendritic cells (mDC). VTX-2337 stimulates IFNγ production from NK cells and increases the cytotoxicity of NK cells against K562 and ADCC by rituximab and trastuzumab. Effects of VTX-2337 on NK cells were, in part, from direct activation as increased IFNγ production and cytotoxic activity were seen with purified NK cells. Finally, VTX-2337 augments ADCC by rituximab in PBMCs with different FcγR3A genotypes (V/V, V/F, and F/F at position 158). Conclusions: VTX-2337 is a novel small-molecule TLR8 agonist that activates monocytes, DCs, and NK cells. Through the activation of NK cells, it has the potential to augment the effectiveness of monoclonal antibody treatments where a polymorphism in FcγR3A limits clinical efficacy. Clin Cancer Res; 18(2); 499–509. ©2011 AACR.

[1]  L. Standish,et al.  TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy , 2011, Clinical Cancer Research.

[2]  M. McElrath,et al.  Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28. , 2011, Blood.

[3]  L. Standish,et al.  Polysaccharide Krestin Is a Novel TLR2 Agonist that Mediates Inhibition of Tumor Growth via Stimulation of CD8 T Cells and NK Cells , 2010, Clinical Cancer Research.

[4]  Soldano Ferrone,et al.  Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Tippmer,et al.  Generation of Th1-Polarizing Dendritic Cells Using the TLR7/8 Agonist CL075 , 2010, The Journal of Immunology.

[6]  S. Akira,et al.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.

[7]  Andrew E. Parker,et al.  Targeting Toll-like receptors: emerging therapeutics? , 2010, Nature Reviews Drug Discovery.

[8]  J. Byrd,et al.  Reciprocal Regulation of Activating and Inhibitory Fcγ Receptors by TLR7/8 Activation: Implications for Tumor Immunotherapy , 2010, Clinical Cancer Research.

[9]  C. Figdor,et al.  Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy , 2010, Cancer Immunology, Immunotherapy.

[10]  J. Plumas,et al.  Plasmacytoid Dendritic Cells Capture and Cross-Present Viral Antigens from Influenza-Virus Exposed Cells , 2009, PloS one.

[11]  B. Redman,et al.  Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF‐3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma , 2009, Cancer.

[12]  Derick R. Peterson,et al.  Phase II study of a TLR‐9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma , 2009, British journal of haematology.

[13]  J. Grandis,et al.  Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells , 2009, Cancer Immunology, Immunotherapy.

[14]  H. Bontkes,et al.  Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC). , 2008, Cancer letters.

[15]  C. Leichman,et al.  Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Z. Berneman,et al.  The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. , 2008, The oncologist.

[17]  A. Musolino,et al.  Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Arthur M. Krieg,et al.  Toll-like receptor 9 (TLR9) agonists in the treatment of cancer , 2008, Oncogene.

[19]  A. Chang,et al.  Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells. , 2007, Surgery.

[20]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[21]  R. Coffman,et al.  Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists , 2007, Nature Medicine.

[22]  J. Battiste,et al.  Oligodeoxynucleotides Differentially Modulate Activation of TLR7 and TLR8 by Imidazoquinolines , 2006, The Journal of Immunology.

[23]  John P. Vasilakos,et al.  Cutting Edge: Activation of Murine TLR8 by a Combination of Imidazoquinoline Immune Response Modifiers and PolyT Oligodeoxynucleotides , 2006, The Journal of Immunology.

[24]  T. Ghosh,et al.  Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses. , 2006, Cellular immunology.

[25]  Jeffrey S. Miller,et al.  Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. , 2006, International immunology.

[26]  W. Carson,et al.  CpG-Containing Oligodeoxynucleotides Act through TLR9 to Enhance the NK Cell Cytokine Response to Antibody-Coated Tumor Cells 1 , 2005, The Journal of Immunology.

[27]  C. Gardiner,et al.  TLR7/8-Mediated Activation of Human NK Cells Results in Accessory Cell-Dependent IFN-γ Production1 , 2005, The Journal of Immunology.

[28]  Francesco Bertoni,et al.  Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1–polarizing program in dendritic cells , 2005, Nature Immunology.

[29]  J. Dalgaard,et al.  Differential capability for phagocytosis of apoptotic and necrotic leukemia cells by human peripheral blood dendritic cell subsets , 2005, Journal of leukocyte biology.

[30]  I. Davis,et al.  Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. , 2005, Blood.

[31]  M. Tomai,et al.  Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8 , 2005, The Journal of Immunology.

[32]  B. Czerniecki,et al.  Rapid High Efficiency Sensitization of CD8+ T Cells to Tumor Antigens by Dendritic Cells Leads to Enhanced Functional Avidity and Direct Tumor Recognition Through an IL-12-Dependent Mechanism 1 , 2003, The Journal of Immunology.

[33]  G. Weiner,et al.  CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. , 2003, Cancer research.

[34]  E. Unanue,et al.  Interferon-producing Cells Fail to Induce Proliferation of Naive T Cells but Can Promote Expansion and T Helper 1 Differentiation of Antigen-experienced Unpolarized T Cells , 2003, The Journal of experimental medicine.

[35]  E. Cowen,et al.  An open case series of patients with basal cell carcinoma treated with topical 5% imiquimod cream. , 2002, Journal of the American Academy of Dermatology.

[36]  G. Trinchieri,et al.  Interleukin-12 in anti-tumor immunity and immunotherapy. , 2002, Cytokine & growth factor reviews.

[37]  S. Akira,et al.  Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway , 2002, Nature Immunology.

[38]  G. Salles,et al.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.

[39]  A. Palucka,et al.  Cross-Priming of Naive Cd8 T Cells against Melanoma Antigens Using Dendritic Cells Loaded with Killed Allogeneic Melanoma Cells , 2000, The Journal of experimental medicine.

[40]  V. Maino,et al.  Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. , 1995, Blood.

[41]  J. Briones,et al.  NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. , 2008, Experimental hematology.